Combination drug therapy for advanced clear cell kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (toripalimab and axitinib) as the first treatment for advanced kidney cancer that has clear cell features. The goal is to see if this drug combo can shrink tumors and possibly allow some patients to avoid or delay surgery to remove the kidney. Participation requires a tumor biopsy that shows a specific immune pattern.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have newly diagnosed advanced kidney cancer with a clear cell component, and not have received treatment for it.
- You must have at least one measurable tumor outside the kidney.
- You must be in good physical condition (ECOG performance status 0 or 1).
- Your organ function must be adequate, including blood, liver, kidney, and thyroid.
- A biopsy of the kidney tumor must show specific immune features (called TLS-positive).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.